Benzinga | Nov 12, 2020 04:14PM EST

Agile Therapeutics Q3 EPS $(0.18), Inline; Reports $71.9M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30

Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 125 percent decrease over losses of $(0.08) per share from the same period last year.